TDMS Study 05704-01 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: IRDC RESORCINOL DATE: 09/18/94
EXPERIMENT: 05704 TEST: 01 TIME: 17:09:54
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: 05700-04 ROUTE: GAVAGE NTP C#: 05970A
PATHOLOGIST: F. VOELKER S. EUSTIS CAS: 108-46-3
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: IRDC RESORCINOL DATE: 09/18/94
EXPERIMENT: 05704 TEST: 01 TIME: 17:09:54
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: 05700-04 ROUTE: GAVAGE NTP C#: 05970A
PATHOLOGIST: F. VOELKER S. EUSTIS CAS: 108-46-3
MICE(B6C3F1)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Gland
Bone Marrow
Brain
Epididymis
Gallbladder
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: IRDC RESORCINOL DATE: 09/18/94
EXPERIMENT: 05704 TEST: 01 TIME: 17:09:54
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: 05700-04 ROUTE: GAVAGE NTP C#: 05970A
PATHOLOGIST: F. VOELKER S. EUSTIS CAS: 108-46-3
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF RESORCINOL
====================================================================================================
MALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Liver Hepatocellular Adenoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Skin: Subcutaneous Tissue Neurofibrosarcoma, Fibrosarcoma, Sarcoma,
Neurofibroma, or Fibroma
Sarcoma
All Organs Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
FEMALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Lung Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma
All Organs Malignant Lymphoma And Histiocytic Sarcoma
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed,
NOS, or Undifferentiated Cell Type
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/47 (0%) 0/0 (0%) 2/49 (4%) | 0/47 (0%) 0/0 (0%) 0/48 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 5.9% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/34 (0%) 0/0 2/34 (6%) | 0/36 (0%) 0/0 0/33 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- 730 (T) | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.143 (e) P=0.238 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.143 (e) P=0.238 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.143 (e) P=0.238 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.149 | (e) |
|FISHER EXACT | (e) P=0.258 | (e) (e) |
|=================================================================================================================================|
| |
|Harderian Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 0/50 (0%) | 0/50 (0%) 0/50 (0%) 1/50 (2%) |
|ADJUSTED (b) | 2.7% 4.7% 0.0% | 0.0% 0.0% 2.9% |
|TERMINAL (d) | 1/37 (3%) 2/43 (5%) 0/34 (0%) | 0/38 (0%) 0/33 (0%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 730 (T) 730 (T) --- | --- --- 730 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.377N P=0.552 P=0.517N | P=0.258 (e) P=0.478 |
|INCIDENTAL TUMOR | P=0.377N P=0.552 P=0.517N | P=0.258 (e) P=0.478 |
|LOGISTIC REGRESSION | P=0.377N P=0.552 P=0.517N | P=0.258 (e) P=0.478 |
|COCHRAN-ARMITAGE | P=0.360N | P=0.270 |
|FISHER EXACT | P=0.500 P=0.500N | (e) P=0.500 |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 0/50 (0%) | 0/50 (0%) 0/50 (0%) 2/50 (4%) |
|ADJUSTED (b) | 2.7% 4.7% 0.0% | 0.0% 0.0% 5.3% |
|TERMINAL (d) | 1/37 (3%) 2/43 (5%) 0/34 (0%) | 0/38 (0%) 0/33 (0%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 730 (T) 730 (T) --- | --- --- 676 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.377N P=0.552 P=0.517N | P=0.095 (e) P=0.228 |
|INCIDENTAL TUMOR | P=0.377N P=0.552 P=0.517N | P=0.121 (e) P=0.286 |
|LOGISTIC REGRESSION | P=0.377N P=0.552 P=0.517N | P=0.092 (e) P=0.227 |
|COCHRAN-ARMITAGE | P=0.360N | P=0.095 |
|FISHER EXACT | P=0.500 P=0.500N | (e) P=0.247 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 7/16 (44%) 4/50 (8%) | 1/50 (2%) 0/5 (0%) 2/50 (4%) |
|ADJUSTED (b) | 15.1% 50.0% 11.3% | 2.6% 0.0% 5.3% |
|TERMINAL (d) | 4/37 (11%) 7/14 (50%) 3/34 (9%) | 1/38 (3%) 0/4 (0%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 700 730 (T) 653 | 730 (T) --- 636 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.402N P=0.052 P=0.444N | P=0.351 P=0.916N P=0.472 |
|INCIDENTAL TUMOR | P=0.497N P=0.017 * P=0.568N | P=0.308 P=0.916N P=0.416 |
|LOGISTIC REGRESSION | P=0.465N P=0.013 * P=0.475N | P=0.370 P=0.916N P=0.487 |
|COCHRAN-ARMITAGE | P=0.334N | P=0.382 |
|FISHER EXACT | P=0.010 * P=0.370N | P=0.909N P=0.500 |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 4/16 (25%) 3/50 (6%) | 1/50 (2%) 1/5 (20%) 3/50 (6%) |
|ADJUSTED (b) | 14.6% 23.1% 8.8% | 2.6% 25.0% 8.0% |
|TERMINAL (d) | 3/37 (8%) 3/14 (21%) 3/34 (9%) | 1/38 (3%) 1/4 (25%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | 635 686 730 (T) | 730 (T) 730 (T) 497 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.260N P=0.563 P=0.302N | P=0.202 P=0.225 P=0.272 |
|INCIDENTAL TUMOR | P=0.350N P=0.163 P=0.369N | P=0.214 P=0.225 P=0.278 |
|LOGISTIC REGRESSION | P=0.299N P=0.202 P=0.326N | P=0.237 P=0.225 P=0.307 |
|COCHRAN-ARMITAGE | P=0.213N | P=0.241 |
|FISHER EXACT | P=0.191 P=0.243N | P=0.175 P=0.309 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 12/50 (24%) 11/16 (69%) 7/50 (14%) | 2/50 (4%) 1/5 (20%) 5/50 (10%) |
|ADJUSTED (b) | 28.3% 72.0% 19.9% | 5.3% 25.0% 13.0% |
|TERMINAL (d) | 7/37 (19%) 10/14 (71%) 6/34 (18%) | 2/38 (5%) 1/4 (25%) 3/34 (9%) |
|FIRST INCIDENCE (DAYS) | 635 686 653 | 730 (T) 730 (T) 497 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.220N P=0.082 P=0.236N | P=0.135 P=0.333 P=0.185 |
|INCIDENTAL TUMOR | P=0.341N P=0.002 ** P=0.350N | P=0.128 P=0.333 P=0.163 |
|LOGISTIC REGRESSION | P=0.284N P=0.003 ** P=0.261N | P=0.165 P=0.333 P=0.211 |
|COCHRAN-ARMITAGE | P=0.151N | P=0.173 |
|FISHER EXACT | P=0.002 ** P=0.154N | P=0.253 P=0.218 |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 12/50 (24%) 11/16 (69%) 7/50 (14%) | 2/50 (4%) 1/5 (20%) 5/50 (10%) |
|ADJUSTED (b) | 28.3% 72.0% 19.9% | 5.3% 25.0% 13.0% |
|TERMINAL (d) | 7/37 (19%) 10/14 (71%) 6/34 (18%) | 2/38 (5%) 1/4 (25%) 3/34 (9%) |
|FIRST INCIDENCE (DAYS) | 635 686 653 | 730 (T) 730 (T) 497 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.220N P=0.082 P=0.236N | P=0.135 P=0.333 P=0.185 |
|INCIDENTAL TUMOR | P=0.341N P=0.002 ** P=0.350N | P=0.128 P=0.333 P=0.163 |
|LOGISTIC REGRESSION | P=0.284N P=0.003 ** P=0.261N | P=0.165 P=0.333 P=0.211 |
|COCHRAN-ARMITAGE | P=0.151N | P=0.173 |
|FISHER EXACT | P=0.002 ** P=0.154N | P=0.253 P=0.218 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 4/7 (57%) 6/50 (12%) | 0/50 (0%) 0/7 (0%) 1/49 (2%) |
|ADJUSTED (b) | 13.5% 75.5% 16.2% | 0.0% 0.0% 2.9% |
|TERMINAL (d) | 5/37 (14%) 3/4 (75%) 4/34 (12%) | 0/38 (0%) 0/3 (0%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 730 (T) 686 209 | --- --- 730 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.371 P=0.008 ** P=0.436 | P=0.287 (e) P=0.478 |
|INCIDENTAL TUMOR | P=0.406 P=0.003 ** P=0.500 | P=0.287 (e) P=0.478 |
|LOGISTIC REGRESSION | P=0.376 P=0.004 ** P=0.458 | P=0.287 (e) P=0.478 |
|COCHRAN-ARMITAGE | P=0.445 | P=0.299 |
|FISHER EXACT | P=0.009 ** P=0.500 | (e) P=0.495 |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/7 (29%) 0/50 (0%) | 0/50 (0%) 3/7 (43%) 0/49 (0%) |
|ADJUSTED (b) | 2.0% 26.6% 0.0% | 0.0% 100.0% 0.0% |
|TERMINAL (d) | 0/37 (0%) 1/4 (25%) 0/34 (0%) | 0/38 (0%) 3/3 (100%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 517 698 --- | --- 730 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.407N P=0.312 P=0.536N | P=0.584 P<0.001 ** (e) |
|INCIDENTAL TUMOR | P=0.461N P=0.022 * P=0.500N | P=0.584 P<0.001 ** (e) |
|LOGISTIC REGRESSION | P=0.355N P=0.009 ** P=0.390N | P=0.584 P<0.001 ** (e) |
|COCHRAN-ARMITAGE | P=0.380N | P=0.616 |
|FISHER EXACT | P=0.037 * P=0.500N | P=0.001 ** (e) |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 6/7 (86%) 6/50 (12%) | 0/50 (0%) 3/7 (43%) 1/49 (2%) |
|ADJUSTED (b) | 15.3% 100.0% 16.2% | 0.0% 100.0% 2.9% |
|TERMINAL (d) | 5/37 (14%) 4/4 (100%) 4/34 (12%) | 0/38 (0%) 3/3 (100%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 517 686 209 | --- 730 (T) 730 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.470 P=0.004 ** P=0.548 | P=0.358 P<0.001 ** P=0.478 |
|INCIDENTAL TUMOR | P=0.484 P<0.001 ** P=0.623 | P=0.358 P<0.001 ** P=0.478 |
|LOGISTIC REGRESSION | P=0.501 P<0.001 ** P=0.613 | P=0.358 P<0.001 ** P=0.478 |
|COCHRAN-ARMITAGE | P=0.551N | P=0.391 |
|FISHER EXACT | P<0.001 ** P=0.620N | P=0.001 ** P=0.495 |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 0/50 (0%) 1/50 (2%) 2/50 (4%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 0.0% 3.0% 5.9% |
|TERMINAL (d) | 0/37 (0%) 0/43 (0%) 0/34 (0%) | 0/38 (0%) 1/33 (3%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | --- 730 (T) 730 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.128 P=0.472 P=0.214 |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.128 P=0.472 P=0.214 |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.128 P=0.472 P=0.214 |
|COCHRAN-ARMITAGE | (e) | P=0.142 |
|FISHER EXACT | (e) (e) | P=0.500 P=0.247 |
|=================================================================================================================================|
| |
|Ovary |
| Cystadenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | | 0/49 (0%) 0/11 (0%) 2/49 (4%) |
|ADJUSTED (b) | | 0.0% 0.0% 6.1% |
|TERMINAL (d) | | 0/37 (0%) 0/10 (0%) 2/33 (6%) |
|FIRST INCIDENCE (DAYS) | | --- --- 730 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.112 (e) P=0.213 |
|INCIDENTAL TUMOR | | P=0.112 (e) P=0.213 |
|LOGISTIC REGRESSION | | P=0.112 (e) P=0.212 |
|COCHRAN-ARMITAGE | | P=0.130 |
|FISHER EXACT | | (e) P=0.247 |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Ovary |
| Luteoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | | 2/49 (4%) 0/11 (0%) 0/49 (0%) |
|ADJUSTED (b) | | 5.4% 0.0% 0.0% |
|TERMINAL (d) | | 2/37 (5%) 0/10 (0%) 0/33 (0%) |
|FIRST INCIDENCE (DAYS) | | 730 (T) --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.144N P=0.552N P=0.264N |
|INCIDENTAL TUMOR | | P=0.144N P=0.552N P=0.264N |
|LOGISTIC REGRESSION | | P=0.144N P=0.552N P=0.262N |
|COCHRAN-ARMITAGE | | P=0.130N |
|FISHER EXACT | | P=0.664N P=0.247N |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/45 (2%) 0/0 (0%) 0/50 (0%) | 8/48 (17%) 5/7 (71%) 10/50 (20%) |
|ADJUSTED (b) | 2.8% 0.0% 0.0% | 21.6% 100.0% 28.6% |
|TERMINAL (d) | 1/36 (3%) 0/0 0/34 (0%) | 8/37 (22%) 5/5 (100%) 9/34 (26%) |
|FIRST INCIDENCE (DAYS) | 730 (T) --- --- | 730 (T) 730 (T) 708 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.319N (e) P=0.511N | P=0.271 P=0.001 ** P=0.317 |
|INCIDENTAL TUMOR | P=0.319N (e) P=0.511N | P=0.304 P=0.001 ** P=0.362 |
|LOGISTIC REGRESSION | P=0.319N (e) P=0.511N | P=0.276 P=0.001 ** P=0.328 |
|COCHRAN-ARMITAGE | P=0.290N | P=0.399 |
|FISHER EXACT | P=1.000N P=0.474N | P=0.006 ** P=0.435 |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 0/50 (0%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 5.0% 2.3% 0.0% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/37 (3%) 1/43 (2%) 0/34 (0%) | 0/38 (0%) 0/33 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 695 730 (T) --- | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.156N P=0.457N P=0.272N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.186N P=0.483N P=0.340N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.161N P=0.490N P=0.271N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.142N | (e) |
|FISHER EXACT | P=0.500N P=0.247N | (e) (e) |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Neurofibrosarcoma, Fibrosarcoma, Sarcoma, |
| Neurofibroma, or Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 8/50 (16%) 6/50 (12%) 2/50 (4%) | 1/50 (2%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 18.9% 12.9% 5.2% | 2.4% 0.0% 0.0% |
|TERMINAL (d) | 4/37 (11%) 3/43 (7%) 0/34 (0%) | 0/38 (0%) 0/33 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 628 651 628 | 697 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.061N P=0.308N P=0.084N | P=0.295N P=0.526N P=0.532N |
|INCIDENTAL TUMOR | P=0.104N P=0.443N P=0.123N | P=0.199N P=0.455N P=0.388N |
|LOGISTIC REGRESSION | P=0.047N* P=0.333N P=0.056N | P=0.277N P=0.509N P=0.507N |
|COCHRAN-ARMITAGE | P=0.037N* | P=0.271N |
|FISHER EXACT | P=0.387N P=0.046N* | P=0.500N P=0.500N |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Neurofibrosarcoma, Fibrosarcoma, or Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 5/50 (10%) 2/50 (4%) | 1/50 (2%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 14.5% 10.7% 5.2% | 2.4% 0.0% 0.0% |
|TERMINAL (d) | 3/37 (8%) 2/43 (5%) 0/34 (0%) | 0/38 (0%) 0/33 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 628 651 628 | 697 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.149N P=0.421N P=0.191N | P=0.295N P=0.526N P=0.532N |
|INCIDENTAL TUMOR | P=0.237N P=0.582N P=0.257N | P=0.199N P=0.455N P=0.388N |
|LOGISTIC REGRESSION | P=0.127N P=0.533N P=0.159N | P=0.277N P=0.509N P=0.507N |
|COCHRAN-ARMITAGE | P=0.107N | P=0.271N |
|FISHER EXACT | P=0.500N P=0.134N | P=0.500N P=0.500N |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 5/50 (10%) 1/50 (2%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 14.5% 10.7% 2.6% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 3/37 (8%) 2/43 (5%) 0/34 (0%) | 0/38 (0%) 0/33 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 628 651 628 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.070N P=0.421N P=0.088N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.112N P=0.582N P=0.107N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.057N P=0.533N P=0.073N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.049N* | (e) |
|FISHER EXACT | P=0.500N P=0.056N | (e) (e) |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 0/50 (0%) 1/50 (2%) | 0/50 (0%) 1/50 (2%) 2/50 (4%) |
|ADJUSTED (b) | 7.9% 0.0% 2.9% | 0.0% 3.0% 5.9% |
|TERMINAL (d) | 2/37 (5%) 0/43 (0%) 1/34 (3%) | 0/38 (0%) 1/33 (3%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | 724 --- 730 (T) | --- 730 (T) 730 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.190N P=0.099N P=0.340N | P=0.128 P=0.472 P=0.214 |
|INCIDENTAL TUMOR | P=0.226N P=0.114N P=0.403N | P=0.128 P=0.472 P=0.214 |
|LOGISTIC REGRESSION | P=0.203N P=0.104N P=0.362N | P=0.128 P=0.472 P=0.214 |
|COCHRAN-ARMITAGE | P=0.177N | P=0.142 |
|FISHER EXACT | P=0.121N P=0.309N | P=0.500 P=0.247 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/49 (2%) 0/0 (0%) 0/50 (0%) | 1/49 (2%) 0/0 (0%) 2/49 (4%) |
|ADJUSTED (b) | 2.7% 0.0% 0.0% | 2.6% 0.0% 5.9% |
|TERMINAL (d) | 1/37 (3%) 0/0 0/34 (0%) | 1/38 (3%) 0/0 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | 730 (T) --- --- | 730 (T) --- 730 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.324N (e) P=0.517N | P=0.348 (e) P=0.461 |
|INCIDENTAL TUMOR | P=0.324N (e) P=0.517N | P=0.348 (e) P=0.461 |
|LOGISTIC REGRESSION | P=0.324N (e) P=0.517N | P=0.348 (e) P=0.461 |
|COCHRAN-ARMITAGE | P=0.305N | P=0.385 |
|FISHER EXACT | P=1.000N P=0.495N | P=1.000N P=0.500 |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 2/50 (4%) 0/50 (0%) 1/50 (2%) |
|ADJUSTED (b) | | 5.3% 0.0% 2.9% |
|TERMINAL (d) | | 2/38 (5%) 0/33 (0%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | | 730 (T) --- 730 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.395N P=0.270N P=0.539N |
|INCIDENTAL TUMOR | | P=0.395N P=0.270N P=0.539N |
|LOGISTIC REGRESSION | | P=0.395N P=0.270N P=0.539N |
|COCHRAN-ARMITAGE | | P=0.362N |
|FISHER EXACT | | P=0.247N P=0.500N |
|=================================================================================================================================|
| |
|All Organs |
| Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 3/50 (6%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 2.7% 0.0% 8.8% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/37 (3%) 0/43 (0%) 3/34 (9%) | 0/38 (0%) 0/33 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 730 (T) --- 730 (T) | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.150 P=0.470N P=0.275 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.150 P=0.470N P=0.275 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.150 P=0.470N P=0.275 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.175 | (e) |
|FISHER EXACT | P=0.500N P=0.309 | (e) (e) |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 4/50 (8%) | 1/50 (2%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 2.7% 0.0% 11.8% | 2.1% 0.0% 0.0% |
|TERMINAL (d) | 1/37 (3%) 0/43 (0%) 4/34 (12%) | 0/38 (0%) 0/33 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 730 (T) --- 730 (T) | 617 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.064 P=0.470N P=0.154 | P=0.285N P=0.532N P=0.513N |
|INCIDENTAL TUMOR | P=0.064 P=0.470N P=0.154 | P=0.307N P=0.433N P=0.602N |
|LOGISTIC REGRESSION | P=0.064 P=0.470N P=0.154 | P=0.257N P=0.477N P=0.477N |
|COCHRAN-ARMITAGE | P=0.081 | P=0.271N |
|FISHER EXACT | P=0.500N P=0.181 | P=0.500N P=0.500N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma And Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 8/50 (16%) 2/50 (4%) | 25/50 (50%) 12/50 (24%) 22/50 (44%) |
|ADJUSTED (b) | 10.3% 18.6% 5.9% | 58.0% 28.5% 62.6% |
|TERMINAL (d) | 3/37 (8%) 8/43 (19%) 2/34 (6%) | 20/38 (53%) 4/33 (12%) 21/34 (62%) |
|FIRST INCIDENCE (DAYS) | 711 730 (T) 730 (T) | 622 582 621 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.346N P=0.256 P=0.385N | P=0.470N P=0.037N* P=0.541N |
|INCIDENTAL TUMOR | P=0.371N P=0.244 P=0.434N | P=0.432N P=0.004N** P=0.518N |
|LOGISTIC REGRESSION | P=0.385N P=0.226 P=0.417N | P=0.396N P=0.011N* P=0.472N |
|COCHRAN-ARMITAGE | P=0.302N | P=0.307N |
|FISHER EXACT | P=0.178 P=0.339N | P=0.006N** P=0.344N |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 8/50 (16%) 2/50 (4%) | 25/50 (50%) 12/50 (24%) 22/50 (44%) |
|ADJUSTED (b) | 10.3% 18.6% 5.9% | 58.0% 28.5% 62.6% |
|TERMINAL (d) | 3/37 (8%) 8/43 (19%) 2/34 (6%) | 20/38 (53%) 4/33 (12%) 21/34 (62%) |
|FIRST INCIDENCE (DAYS) | 711 730 (T) 730 (T) | 622 582 621 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.346N P=0.256 P=0.385N | P=0.470N P=0.037N* P=0.541N |
|INCIDENTAL TUMOR | P=0.371N P=0.244 P=0.434N | P=0.432N P=0.004N** P=0.518N |
|LOGISTIC REGRESSION | P=0.385N P=0.226 P=0.417N | P=0.396N P=0.011N* P=0.472N |
|COCHRAN-ARMITAGE | P=0.302N | P=0.307N |
|FISHER EXACT | P=0.178 P=0.339N | P=0.006N** P=0.344N |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 21/50 (42%) 15/50 (30%) 15/50 (30%) | 16/50 (32%) 8/50 (16%) 16/50 (32%) |
|ADJUSTED (b) | 51.0% 34.0% 40.2% | 42.1% 23.4% 44.2% |
|TERMINAL (d) | 17/37 (46%) 14/43 (33%) 12/34 (35%) | 16/38 (42%) 7/33 (21%) 14/34 (41%) |
|FIRST INCIDENCE (DAYS) | 695 686 209 | 730 (T) 699 636 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.201N P=0.062N P=0.257N | P=0.406 P=0.096N P=0.433 |
|INCIDENTAL TUMOR | P=0.223N P=0.071N P=0.315N | P=0.436 P=0.089N P=0.442 |
|LOGISTIC REGRESSION | P=0.250N P=0.084N P=0.306N | P=0.425 P=0.096N P=0.457 |
|COCHRAN-ARMITAGE | P=0.123N | P=0.543 |
|FISHER EXACT | P=0.149N P=0.149N | P=0.050N P=0.585N |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 112MG/KG 225MG/KG | CONTROL 112MG/KG 225MG/KG |
| | M MALE MALE | F FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 18/50 (36%) 19/50 (38%) 9/50 (18%) | 29/50 (58%) 17/50 (34%) 27/50 (54%) |
|ADJUSTED (b) | 39.7% 39.6% 24.0% | 63.0% 40.8% 72.6% |
|TERMINAL (d) | 10/37 (27%) 14/43 (33%) 6/34 (18%) | 21/38 (55%) 9/33 (27%) 24/34 (71%) |
|FIRST INCIDENCE (DAYS) | 517 651 628 | 617 582 497 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.080N P=0.475N P=0.093N | P=0.497 P=0.083N P=0.509 |
|INCIDENTAL TUMOR | P=0.128N P=0.398 P=0.123N | P=0.535N P=0.008N** P=0.551 |
|LOGISTIC REGRESSION | P=0.067N P=0.475 P=0.072N | P=0.491N P=0.023N* P=0.559N |
|COCHRAN-ARMITAGE | P=0.032N* | P=0.385N |
|FISHER EXACT | P=0.500 P=0.035N* | P=0.013N* P=0.420N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 33/50 (66%) 29/50 (58%) 22/50 (44%) | 35/50 (70%) 21/50 (42%) 33/50 (66%) |
|ADJUSTED (b) | 70.2% 60.4% 56.2% | 76.1% 49.7% 84.4% |
|TERMINAL (d) | 23/37 (62%) 24/43 (56%) 17/34 (50%) | 27/38 (71%) 12/33 (36%) 28/34 (82%) |
|FIRST INCIDENCE (DAYS) | 517 651 209 | 617 582 497 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.079N P=0.112N P=0.107N | P=0.454 P=0.057N P=0.460 |
|INCIDENTAL TUMOR | P=0.099N P=0.231N P=0.122N | P=0.527 P=0.003N** P=0.507 |
|LOGISTIC REGRESSION | P=0.072N P=0.212N P=0.090N | P=0.525N P=0.009N** P=0.584 |
|COCHRAN-ARMITAGE | P=0.017N* | P=0.383N |
|FISHER EXACT | P=0.268N P=0.022N* | P=0.004N** P=0.415N |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05704 TEST: 01 PAGE 15
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- RESORCINOL
TERMINAL SACRIFICE AT 105 WEEKS
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).